Mechanisms and clinical effects of thiazolidinediones

Bibliography

• WHITCOMB RW, SALTIEL AR: Thiazolidinediones. Exp. Opin. Invest. Drugs (1995) 4:1299–1309.
   Google Scholar
• ERIKSSON J, FRANSSILA-KALLUNKI A, EKSTRAND A et al.: Early metabolic defects in persons at increased risk for non-insulin dependent diabetes mellitus. New Eng. J. Med. (1989) 321:337–343.
   PubMed Web of Science ®Google Scholar
• WARRAM JH, MARTIN BC, KROLEWSKI AS, SOELDNER JS,KAHN CR: Slow glucose removal rate and hyperin-sulinemia precede the development of type 11 diabetes in the offspring of diabetic parents. Ann. Intern. Med. (1990) 113:909–915.
   PubMed Web of Science ®Google Scholar
• MARTIN BC, WARRAM JH, KROLEWSKI AS et al: Role ofglucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet (1990) 340:925–929.
   Web of Science ®Google Scholar
• LILLIOJA S, MOTT DM, SPRAUL M et al: Insulin resistanceand insulin secretory dysfunction as precursors of non-insulin dependent diabetes mellitus. New Eng. J. Med. (1993) 329:1988–1992.
   PubMed Web of Science ®Google Scholar
• SKAFORS ET, SELINUS KI, LITHELL HO: Risk factors fordeveloping non-insulin dependent diabetes: a 10 year follow up of men in Uppsala. Br. Med. J. (1991) 303:755–760
   PubMed Web of Science ®Google Scholar
• SAAD MF, KNOWLER WC, PETTITT DJ et al: Sequential changes in serum insulin concentration during devel-opment of non-insulin dependent diabetes. Lancet (1989)1356–1359.
   PubMed Web of Science ®Google Scholar
• LILLIOJA S, MOTT DM, HOWARD et al.: Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. New Eng. J. Med. (1988) 318:1217–25.
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA, FERRANNINI E: Insulin resistance: amultifaceted syndrome response for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic car-diovascular disease. DiabeL Care (1991) 14:173.
   PubMed Web of Science ®Google Scholar
• REAVEN GM. Role of insulin resistance in human dis-ease. Diabetes (1988) 37:1595–607.
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA: Pathogenesis of type 2 (non-insulin dependent diabetes mellitus: a balanced overview. Di-abetologia (1992) 35:389–397.
   PubMed Web of Science ®Google Scholar
• CZECH MP, CANCY BM, PESSINO A, WOON CW, HARRI-SON SA: Complex regulation of simple sugar transport in insulin-responsive cells. Trend Biol. Sci. (1992) 17:197–201.
   PubMed Web of Science ®Google Scholar
• KAHN CR: Insulin action, diabetogenes, and the cause of type 11 diabetes. Diabetes (1994) 43:1066–1084.
   PubMed Web of Science ®Google Scholar
• LEMARCHAND-BRUSTEL Y, GREMEAUX T, BALLOTTI R, VAN OBBERGHEN E: Insulin receptor tyrosine kinase is defective in skeletal muscle of insulin-resistant obese mice. Nature (1985) 315:676–679.
   PubMed Web of Science ®Google Scholar
• SALTIEL AR: Diverse signaling pathways in the cellular actions of insulin. Am. J. Physiol (Endocrinol Metab. 33) (1996) 270:E375–E385.
   PubMed Web of Science ®Google Scholar
• FARESE RV: Insulin-sensitive phospholipid signaling systems and glucose transport: an update. Proc. Soc. Exp. Biol. Med. (1996) 213:1–12.
   PubMed Web of Science ®Google Scholar
• REAVEN GM: Pathophysiology of insulin resistance in human disease. Physiol. Rev. (1995) 75:473–486.
   PubMed Web of Science ®Google Scholar
• HOWARD G, O'LEARY DH, ZACCARO D et al: Insulin sensitivity and atherosclerosis. Circulation (1996) 93:1809–1817.
   PubMed Web of Science ®Google Scholar
• LEE M-K, MILES PDG, KHOURSHEED M et al.: Metaboliceffects of troglitazone on fructose-induced insulin re-sistance in the rat. Diabetes (1994) 43:1435–1439.
   PubMed Web of Science ®Google Scholar
• KOURSHEED M, MILES PDG, GAO K-M et al.: Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. Metabolism (1995) 44:1489–1494.
   PubMed Web of Science ®Google Scholar
• KAUFMAN LN, PETERSON MM, DEGRANGE LM: Pioglita-zone attenuates diet-induced hypertension in rats. Me-tabolism (1995) 44:1105–1109.
   PubMed Web of Science ®Google Scholar
• IKEDA H, TAKETOMI S, SUGIYAMA Y et al.: Effects of pioglitazone on glucose and lipid metabolism in nor-mal and insulin resistant animals. Arzneim.-Forsch./Drug Res. (1990) 40:156–62.
   PubMed Web of Science ®Google Scholar
• SUGIYAMA Y, SHIMURA Y, IKEDA H: Effects of pioglita-zone on hepatic and peripheral resistance in Wistar fatty rats. Arzneim.-Forsch./Drug Res. (1990) 40(I):436–440.
   Google Scholar
• KOBAYASHI M, IWANISHI M, EGAWA K etal: Pioglitazone increases insulin sensitivity by activating insulin recep-tor kinase. Diabetes (1992) 41:476–483.
   PubMed Web of Science ®Google Scholar
• ELDERSHAW TPD, RATTIGAN S, CAWTHORNE MA et al.: Treatment with the thiazolidinedione (BRL 49653) de-creases insulin resistance in obese Zucker hindlimb. Horm. Metab. Res. (1995) 27:169–172.
   PubMed Web of Science ®Google Scholar
• YOUNG PW, CAWTHORNE MA, COYLE PJ et al.: Repeat treatment of obese mice with Bill 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell surface GLUT4 as measured by pho-toaffinity labeling. Diabetes (1995) 44:1087–1092.
   Google Scholar
• STEVENSON RW, HUTSON NJ, MICHAEL NK et al.: Actions of novel antidiabetic agent englitazone in hyperglyce-mic hyperinsulinemic ob/ob mice. Diabetes (1990) 39:1218–1227.
   PubMed Web of Science ®Google Scholar
• KEMNITZ JW, ELSON DF, ROECKER EB et al: Pioglitazoneincreases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys. Diabetes (1994) 43:204–11.
   PubMed Web of Science ®Google Scholar
• FAME RV: Insulin-sensitive phospholipid signalingsystems and glucose transport: an update. Proc. Soc. Exp. Biol. Med. (1996) 213:1–12.
   PubMed Web of Science ®Google Scholar
• OKADA T, KAWANO Y, SAKAKIBARA T, HAZEKI 0, MICHIO U: Essential role of PI-3 kinase in insulin-in-duced glucose transport and antilipolysis in rat adipo-cytes. J. Biol. Chem. (1994) 269:3568–3573.
   PubMed Web of Science ®Google Scholar
• KELLERER M, KRODER G, TIPPMER S et al. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes (1994) 43:447–453.
   PubMed Web of Science ®Google Scholar
• MAEGAWA H, IDE R, HASEGAWA M et al.: Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities. J. Biol. Chem. (1995) 270:7724–7730.
   PubMed Web of Science ®Google Scholar
• KRODER G, BOSSENMAIER B, KELLERER M et al.: Tumornecrosis factor-alpha-and hyperglycemia-induced in-sulin resistance. Evidence for different mechanisms and different effects on insulin signaling. J. Clin. Invest. (1996) 97:1471–1477.
   Google Scholar
• ZHANG B, SZALKOWSKI D, DIAZ E et al: Potentiation ofinsulin stimulation of p hosphatidylinositol 3-kinase by thiazolidinedione-derived antidiabetic agents in Chi-nese hamster ovary cells expressing human insulin receptors and L6 myotubes. J. Biol. Chem. (1994) 269:25735–25741.
   PubMed Web of Science ®Google Scholar
• HAYAKAWA T, SHIRAKI T, MORIMOTO T, SHII K, IKEDA H: Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats. Biochem. Biophys. Res. Comm. (1996) 223:439–444.
   PubMed Web of Science ®Google Scholar
• SAGHIZADEH M, ONG JM, GARVEY WT eta].: Expression of TNF-a by human muscle. Relationship to insulin resistance. J. Clin. Invest. (1996) 97:1111–1116.
   Google Scholar
• HOTAMISLIGIL GS, SHARGILL NS, SPIEGELMAN BM: Adi-pose expression of tumor necrosis factor-a: direct role in obesity-linked insulin resistance. Science (1993) 259:87–91.
   PubMed Web of Science ®Google Scholar
• HOTAMISLIGIL GS, SPIEGELMAN BM: Tumor necrosis factor a: a key component of obesity-diabetes link. Diabetes (1994) 43:1271–1278.
   PubMed Web of Science ®Google Scholar
• HOTAMISLIGIL GS, BUDAVARI A, MURRAY D, SPIEGEL-MAN BM: Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J. Clin. Invest. (1994) 94:1543–1549.
   Google Scholar
• HOTAMISLIGIL GS, PERALDI P, BUDAVARI A et al: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity of TNF-a and obesity-induced insulin resis-tance. Science (1996) 271:665–668.
   PubMed Web of Science ®Google Scholar
• STEPHENS JM, PEKALA PH: Transcriptional repression of the GLUT4 and C/EBP genes in 3T341 adipocytes by tumor necrosis factor a. J. Biol. Chem. (1991) 266:21839–21845.
   PubMed Web of Science ®Google Scholar
• OHSUMI J, SAKAKIBARA S, YAMAGUCHI J et al.: Troglita-zone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology (1994) 135:2279–2282.
   PubMed Web of Science ®Google Scholar
• SZALKOWSKI D, WHITE-CARRINGTON S, BERGER J et al.: Anti-diabetic thiazolidinediones block inhibitory effect of tumor necrosis factor alpha on differentiation, insu-lin stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology (1994) 136:1474–1481.
   Web of Science ®Google Scholar
• HOFMANN C, LORENZ K, BRAITHWAITE SS etal.: Altered gene expression for tumor necrosis factor-a and its receptors during drug and dietary modulation of insu-lin resistance. Endocrinology 134:264–270.
   Google Scholar
• SANDOUK T, REDA D, HOFMANN C: Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells. Am. J. Physiol. (1993) 264:C1600–1608.
   PubMed Web of Science ®Google Scholar
• SANDOUK T, REDA D, HOFMANN C: The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messen-ger ribonucleic acid transcript stability. Endocrinology (1993) 133:352–359.
   PubMed Web of Science ®Google Scholar
• HOFMANN C, LORENZ K, COLCA JR: Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology (1991) 129:1915–1925.
   PubMed Web of Science ®Google Scholar
• HIRSHMAN MF, FAGNANT PM, HORTON ED, KING PA, HORTON ES: Pioglitazone treatment for 7 days failed to correct the defect in glucose transport and glucose transporter translocation in obese zucker rat (fa/fa) skeletal muscle plasma membranes. Bio. Chem. & Bio. Phys. Res. Comm. (1995) 208:835–845.
   PubMed Web of Science ®Google Scholar
• TONTONOZ P, HU E, GRAVES RA et al.: mPPARgamma2: tissue-specific regulator of an adipocyte enhancer. Genes and Dev. (1994) 8:1224–1234.
   PubMed Web of Science ®Google Scholar
• CHAWLA A, SCHWARTZ E, DIMACULANGAN DD et al.:Pe roxis ome p rol ife rator -activated receptor (PPAR): adi-pose-predominant expression and induction early in adipocyte differentiation. Endocrinology (1994) 135:798–800.
   PubMed Web of Science ®Google Scholar
• ZHU Y, ALVARES K, HUANG Q, M. SAMBASIVA R, REDDY JK: Cloning of a new member of the peroxisome prolif-erator-activated receptor gene family from mouse liver. J. Biol. Chem. (1993) 268:26817–26820.
   PubMed Web of Science ®Google Scholar
• BRAISSANT 0, FOUFELLE F, SCOTTO C et al.: Differential expression of peroxisome proliferator-activated recep-tors (PPARs): tissue distribution of PPAR-y, and in the adult rat. Endocrinology (1996) 137:354–366.
   Google Scholar
• LAMB KG, TUGWOOD JD: A human peroxisome-prolif-erator-activated receptor-gamma is activated by in-ducers of adipogenesis, including thiazolidinedione drugs. Eur.J. Biochem. (1996) 239:1–7.
   PubMedGoogle Scholar
• ELBRECHT A, YULI CHEN CA, CULLINAN CA, ET AL: Mo-lecular cloning, expression and characterization of human peroxisome proliferator activated receptors 1 and 2. Bio. Chem. Phys. Res. Comm. (1996) 224:431–437.
   PubMed Web of Science ®Google Scholar
• VIDAL-PUIG A, JIMINEZ-LINAN M, LOWELL BB et al: Regu-lation of PPAR-y gene expression by nutrition and obesity in rodents. J. Clin. Invest. (1996) 97:2553–2561.
   PubMed Web of Science ®Google Scholar
• LEHMANN JM, MOORE LB, LEHMAN JM eta].: An antidia-betic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR-y). J. Biol. Chem. (1995) 270:12953–12956.
   Google Scholar
• YU K, BAYONA W, KALLEN CB et al: Differential activa-tion of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. (1995) 270:23975–23983.
   PubMed Web of Science ®Google Scholar
• BERGER J, BAILEY P, BISWAS C et al.: Thiazolidinediones produce a conformational change in peroxisomal pro-life rator-activated receptor gamma: binding and activa-tion correlate with antidiabetic actions in db/db mice. Endocrinology (1996) 137:4189–4195.
   PubMed Web of Science ®Google Scholar
• CHAWLA A AND LAZAR MA: Peroxisome proliferator and retinoid signaling pathways co-regulate preadipocyte phenotype and survival. Proc. Natl. Acad. Sci. USA (1994) 91:1786–1790.
   PubMed Web of Science ®Google Scholar
• TAFURI SR: Troglitzone enhances differentiation, basalglucose uptake, and Glutl protein levels in 3T3-L1 adipocytes. Endocrinology (1996) 137:4706–4712.
   PubMed Web of Science ®Google Scholar
• TONTONOZ P, HU E, SPIEGELMAN BM: Stimulation ofadipogenesis in fibroblasts by PPAR2, a lipid-activated transcription factor. Cell (1994) 79:1147–1156.
   PubMed Web of Science ®Google Scholar
• DE VOS P, LEFEBVRE AM, MILLER SG et al.: Thiazolidi-nediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated recep-tor gamma. J. Clin. Invest. (1996) 98:1004–1009.
   PubMed Web of Science ®Google Scholar
• RANDLE PJ, GARLAND PB, HALES CN, NEWSHOLME EA:The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes melitus. Lancet (1963) 1:785–789.
   PubMed Web of Science ®Google Scholar
• RANDLE PJ, NEWSHOLME EA, GARLAND PB: Regulationof glucose uptake by muscle:effects of fatty adds, ke-tone bodies and pyruvate, and of alloxan-diabetes and starvation on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem. J. (1964) 93:652–665.
   PubMed Web of Science ®Google Scholar
• TEBOUL L, GAILLARD D, STACCINI L et al.: Thiazolidi-nediones and fatty acids convert myogenic cells into adipose-like cells. J. Biol. Chem. (1995) 270:28183–28187.
   PubMed Web of Science ®Google Scholar
• CAMPFIELD LA, SMITH FJ, GUISFZ Y, DEVOS R, BURN P: Recombinant mouse OB protein: evidence for a periph-eral signal linking adiposity and central neuronal net-works. Science (1995) 269:546–549.
   PubMed Web of Science ®Google Scholar
• KALLEN CB AND LAZAR MA: Antidiabetic thiazolidi-nediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. USA (1996) 93:5793–5796.
   PubMed Web of Science ®Google Scholar
• ZHANG B, GRAZIANO MP, DOEBBER TW et al.: Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J. Biol. Chem. (1996) 271:9455–9459.
   PubMed Web of Science ®Google Scholar
• NOLAN JJ, OLEFSKY JM, NYCE MR, CONSIDINE RV, CAROJF: Effect of troglitazone on letin production. Studies in vitro and in human subjects. Diabetes (1996) 45:1276–1278.
   Google Scholar
• PEARSON SL, CAWTHORNE MA, CLAPHAM JC et al.: Thethiazolidinedione insulin sensitizer, BRL 49653, in-creases the expression of PPAR-gamma and aP2 in adipose tissue of high-fat-fed rats. Biochem. Biophys. Res. Commun. (1996) 229:752–757.
   PubMed Web of Science ®Google Scholar
• OAKES ND, KENNEDY CJ, JENKINS AB et al.: A newantidiabetic agent, BIM 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes (1994) 43:1203–1210.
   PubMed Web of Science ®Google Scholar
• BOWEN L, STEIN PP, STEVENSON R, SHULMAN GI: Theeffect of CP 68, 722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats. Meta-bolism (1991) 40:1025–1030.
   PubMed Web of Science ®Google Scholar
• SUGIYAMA Y, SHIMURA Y, IKEDA: Effects of pioglitazoneon hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneim.-Forsch. (1990) 40:436–440.
   PubMed Web of Science ®Google Scholar
• INOUE I, TAKAHASHI K, KATAYAMA S et al.: Effect of troglitazone (CS-045) and bezafibrate on glucose toler-ance, liver glycogen synthesis activity, and beta-oxida-tion in fructose-fed rats. Metabolism (1995) 44: 1626-1630.
   Google Scholar
• FULGENICO JP, KOHL C, GIRARD J, PEGORIER JP: Trogli-tazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes (1996) 45:1556–1562.
   PubMed Web of Science ®Google Scholar
• MURANO K, INOUE Y, EMOTO M, KAKU K, KANEKO T: CS-045, a new oral intidiabetic agent, stimulates fruc-tose-2, 6-bisphosphate production in rat hepatocytes. Elsevier Science (1995) 254:257–262.
   Google Scholar
• CIARALDI TP, GILMORE A, OLEFSKY JM, GOLDBERG M,HEIDENREICH KA et al.: In vitro studies on the action of CS-045, a new anti-diabetic agent. Metabolism (1990) 39:1056–1062.
   Google Scholar
• YOUNG MA, DONOGHUE S, WILLIAMS ZV, EASTMOND R:Similar pharmacokinetics of troglitazone in young and elderly. 32nd Annual MeetingEuropean Association for the study of Diabetes (1996) Vienna. Poster.
   Google Scholar
• PUCHLER K, SASAHARA K, WASSERHESS P, WITTE PV: Lackof pharmacokinetic interaction between troglitazone and glibenclamide in NIDDM patients. 32nd Annual Meeting of the European Association for the study of Diabetes (1996) Abstract 880.
   Google Scholar
• NOLAN JJ, LUDVIK B, BEERDSEN P, JOYCE M, OLEFSKY J:Improvement in glucose tolerance and insulin resis-tance in obese subjects treated with troglitazone. New Engl. J. Med. (1994) 331:1188–1193.
   PubMed Web of Science ®Google Scholar
• ONUMA T, TSUTSI M, GOTO T, BOKU A, TAKEBE K: Theeffect of a new oral hypoglycemic drug, CS-045, on glucose tolerance and serum lipids in non obese Japa-nese patients with non-insulin dependent diabetes mel-litus; a pilot study. Curr. Ther. Res. (1994) 55:416–421.
   Web of Science ®Google Scholar
• MIMURA K, UMEDA F, HIRAMATSU S et al.: Effects of anew oral hypoglycemic agent (CS-045) on metabolic abnormalities and insulin resistance in Type 2 Diabetes. Diabet. Med. (1994) 11:685–691.
   PubMed Web of Science ®Google Scholar
• SIRONI A, VICKI S, GASTALDELLI A et al.: Effects oftroglitazone on insulin sensitivity and cardiovascular risk factors (CVRF) in NIDDM. Poster at 56th Annual Meeting of the ADA (1996) San Francisco.
   Google Scholar
• KUZUYA MT, IWAMOTO Y, KOSAKA K et al.: A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes melli-tus. Diabet. Res. Clin. Pract. (1991) 11:147–154.
   PubMed Web of Science ®Google Scholar
• KUMAR S, BOULTON HJM, BECK-NIELSEN H et al.: Trogli-tazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia (1996) 39:701–709.
   PubMed Web of Science ®Google Scholar
• IWAMOTO Y, KOSAKA K, KUZUYA T et al.: Effects of troglitazone. A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabet. Care (1996) 19:151–159.
   PubMed Web of Science ®Google Scholar
• VALIQUETT T, BALGTAS C, WHITCOMB R: Troglitazone dose-response study in patients with NIDDM. Diabetes (1995) 44\(Suppl. 2):109A.
   Google Scholar
• GHAZZI M, PEREZ J, ANTONUCCI T et al.: Cardiac andglycemic benefits of troglitazone treatment in NIDDM. Diabetes (1997) 46:433–439.
   PubMed Web of Science ®Google Scholar
• Internal Communication.
   Google Scholar
• HIRAGA K: Results of clinical Phase I study on AD-4833 - single dose and repeated dose studies in healthy adult subjects. Jap. j Clin. Exp. Med. (1997).
   Google Scholar
• WASADA T, OMORI Y, SASAKI H et al.: Effect of pioglita-zone (AD-4833) on insulin stimulated glucose disposal in NIDDM. An assessment by the euglycemic hyperin-sulinemic clamp method. Diabetes (1996) 45\(Suppl. 2):73A.
   Google Scholar
• KANEKO T et al.: Dose finding study of AD-4833 in patients with insulin non-dependent diabetes mellitus (NIDDM) on diet therapy alone - double-blind compara-tive study on four dosages. Jap. J. Clin. Exp. Med. (1997). (In Press).
   Google Scholar
• KANEKO T et al.: Dose finding study of AD-4833 in patients with insulin non-dependent diabetes mellitus (NIDDM) on treatment with an SU drug - double-blind comparative study on four dosages.Jap. J. Clin. Exp. Med. (1997). (In Press).
   Google Scholar
• KANEKO T et al.: Clinical evaluation of an insulin-resis-tance improving drug, AD-4833, in patients with insulin non-diabetes mellitus - a placebo-controlled double-blind comparative study. Jap. J. Clin. Exp. Med. (1997). (In Press).
   Google Scholar
• KANEKO T eta].: Clinical evaluation of an insulin-resis-tance improving drug, AD-4833, in patients with insulin non-dependent diabetes mellitus on treatment with an SU drug - double-blind comparative study on four dosages. Jap. J. Clin. Exp. Med. (1997). (In Press).
   Google Scholar
• FUJIWARA T, WADA M, FUKUDA K eta].: Characterization of CS-045, a new oral antidibetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/Ksj-db/db mice. Metabolism (1991) 40:1213–1218.
   Google Scholar
• OGIHARA T, RAKUGI H, IKEGAMI H, MIKAMI H, MASUO K: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am. J. Hypertens. (1995) 8:316–320.
   PubMed Web of Science ®Google Scholar
• DUNAIF A, SEDT D, FINEGGOD D, QUINTANA B, WHIT-COMB R: The insulin-sensitizing agent troglitazone im-proves metabolic and reproductive abnormalities in the polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. (1996) 81:3299–3306.
   PubMed Web of Science ®Google Scholar
• BERKOWITZ K, PETERS R, KJOS S eta].: Insulin sensitivity and B cell function in women with prior gestational diabetes. Diabetes (1996) 45 (Suppl. 2):57A. Scott L Grossmant & Jan Lessem
   Google Scholar